about
Immune phenotype in children with therapy-naïve remitted and relapsed Crohn's diseaseAdaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy.Dexamethasone protects from renal ischemia/reperfusion injury: a possible association with SGK-1.Gender differences in serum and glucocorticoid regulated kinase-1 (SGK-1) expression during renal ischemia/reperfusion injury.Effect of cigarette smoke and dexamethasone on Hsp72 system of alveolar epithelial cells.Immunoreactive endomorphin 2 is generated extracellularly in rat isolated L4,5 dorsal root ganglia by DPP-IV.[Akt enzyme: new therapeutic target in cancer and diabetes?].T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy.Maternal cytokine balance on the third postpartum day is not affected by the mode of delivery after healthy pregnancies.Immune Phenotype of Children with Newly Diagnosed and Gluten-Free Diet-Treated Celiac DiseasePeripheral dendritic cells in asthmaFoxP3+ regulatory T cells in childhood allergic rhinitis and asthmaSoluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsiaSerum maternal hepcidin levels 3 days after delivery are higher compared to those measured at parturitionSuccessful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapyPlasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis[Increased hepcidin levels three days after gynecological interventions]Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus
P50
Q34428774-DA46DCB5-4061-49D7-A5C1-F9D055B7787FQ35239156-D076B19E-B5BA-4FB4-A263-3475595C1F1EQ39176606-EB594423-DD04-40AF-AE84-689B5B866A6CQ39521029-286AC0C4-62AA-4B1B-B996-0C8902E4FA96Q39614964-1883545F-71DA-42D4-9ABD-0C3486DFA26DQ45961394-DFDC158A-5D96-44FA-8BDE-63E918BE3257Q46121606-5A0E0129-32C5-4825-81F4-FB6DA7DDF676Q47131694-37AE3D1B-2199-4C50-A904-BB4C110EB8E8Q48373084-D0197C76-9E43-440B-8848-6D6277C41FF5Q58763330-781E9822-7C42-406D-B709-DE7B560380CFQ83227711-707B96FF-40C3-45D3-88D7-AA9C696880D0Q84244964-8D16A1A5-B2D4-4F09-9396-7252FC87D0ADQ84487556-01D3CC8F-7E72-4DF2-8956-E9158924B12AQ84511884-275E7320-D830-4C8D-8A28-704C50D8545BQ84983862-DF64F1FC-7E5B-4428-BCE9-95B45AF3D02BQ85015979-5EFA0A78-DDF7-4790-8645-915AEF63710EQ85183640-4EC33851-40C5-4455-8A3C-0B81F16D3250Q87407313-A5CB802B-265C-4E50-AAC3-9664EF70F652
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Balazs Szalay
@en
Balazs Szalay
@nl
type
label
Balazs Szalay
@en
Balazs Szalay
@nl
prefLabel
Balazs Szalay
@en
Balazs Szalay
@nl
P31
P496
0000-0002-7132-143X